BIOSUPERIOR TECHNOLOGY INC

LOS ALTOS, CA · Biotech · Private

Synthetic lung surfactant with bioengineered proteins, phospholipids, and anti-inflammatory agents for neonatal respiratory disease

bio-superior.com →
Grants
$256K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
7
0 granted · 7 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I:Bioengineering lung surfactant for the treatment of respiratory disease$255,987
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2183City Therapeutics——
2184CENNA BIOSCIENCES INC——
2185OCULOGENEX——
2186BIOSUPERIOR TECHNOLOGY INC——
2187NexImmune, Inc.—$35M
2188Platform Therapeutics, Inc.—$1.8M
2189Ceapro Inc.—$7.7M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 7
  • Lung Treatment Compositionsapplication
  • Polypeptides For Lung Surfactant Compositionsapplication
  • Delivery Of Focal Adhesion Kinase For Treating Vascular And/or Capillary Tissue Injuryapplication
  • Polypeptides For Lung Surfactant Compositionsapplication
  • Delivery Of Focal Adhesion Kinase For Treating Vascular And/or Capillary Tissue Injuryapplication
  • Lung Treatment Compositionsapplication
  • Polypeptides For Lung Surfactant Compositionsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.